While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

After Merck KGaA's recent confirmation that it's in "advanced discussions" to acquire SpringWorks Therapeutics, the Connecticut rare disease specialist has boosted its value with a new FDA nod.

The Gomekli approval comes as SpringWorks has emerged as a potential acquisition target for Merck KGaA. Following a Reuters report of negotiations for a deal, the German company issued a statement ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition talks with SpringWorks ...